Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.
Jayson GC, Mulatero C, Ranson M, Zweit J, Jackson A, Broughton L, Wagstaff J, Hakansson L, Groenewegen G, Lawrance J, Tang M, Wauk L, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H; European Organisation for Research and Treatment of Cancer (EORTC). Jayson GC, et al. Among authors: zwierzina h. Eur J Cancer. 2005 Mar;41(4):555-63. doi: 10.1016/j.ejca.2004.11.021. Epub 2005 Jan 22. Eur J Cancer. 2005. PMID: 15737560 Clinical Trial.
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang M, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H; European Organisation for Research and Treatment of Cancer Biological Therapeutic Development Group. Jayson GC, et al. Among authors: zwierzina h. J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93. doi: 10.1093/jnci/94.19.1484. J Natl Cancer Inst. 2002. PMID: 12359857 Clinical Trial.
Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001).
Bergmann L, Aamdal S, Marreaud S, Lacombe D, Herold M, Yamaguchi T, Wilhelm-Ogunbiyi K, Lentzen H, Zwierzina H; European Organisation for Research and Treatment of Cancer. Bergmann L, et al. Among authors: zwierzina h. Eur J Cancer. 2008 Aug;44(12):1657-62. doi: 10.1016/j.ejca.2008.05.005. Epub 2008 Jul 2. Eur J Cancer. 2008. PMID: 18602257 Clinical Trial.
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
Schöffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, Lacombe D, Baron B, Herold M, Zwierzina H, Wilhelm-Ogunbiyi K, Lentzen H, Twelves C; European Organization for Research and Treatment of Cancer New Drug Development Group. Schöffski P, et al. Among authors: zwierzina h. Ann Oncol. 2004 Dec;15(12):1816-24. doi: 10.1093/annonc/mdh469. Ann Oncol. 2004. PMID: 15550588 Free article. Clinical Trial.
Improving the efficacy of cancer immunotherapy.
Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Zwierzina H, Håkansson L. Copier J, et al. Among authors: zwierzina h. Eur J Cancer. 2009 May;45(8):1424-31. doi: 10.1016/j.ejca.2008.12.017. Epub 2009 Jan 21. Eur J Cancer. 2009. PMID: 19167214 Review.
Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
Vassal G, Rousseau R, Blanc P, Moreno L, Bode G, Schwoch S, Schrappe M, Skolnik J, Bergman L, Bradley-Garelik MB, Saha V, Pearson A, Zwierzina H. Vassal G, et al. Among authors: zwierzina h. Eur J Cancer. 2015 Jan;51(2):218-24. doi: 10.1016/j.ejca.2014.10.029. Epub 2014 Nov 27. Eur J Cancer. 2015. PMID: 25434924 Free article.
Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells.
Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Müller-Holzner E, Offner F, Feichtinger H, Zwierzina H, Daxenbichler G. Marth C, et al. Among authors: zwierzina h. Int J Cancer. 1996 Sep 17;67(6):826-30. doi: 10.1002/(SICI)1097-0215(19960917)67:6<826::AID-IJC12>3.0.CO;2-#. Int J Cancer. 1996. PMID: 8824555 Free article.
112 results